Read More

Tevogen Bio CEO Highlights Expected Reporting Of A $94.9M Liability Elimination; Tevogen.ai Initiative Aims To Harness The Immense Potential Of AI To Enhance Drug Discovery, Development, Manufacturing, Distribution, And Patient Access

Conversion of promissory notes into common stock removed $94.9 million in pro forma balance sheet liabilities.The converted common stock is included in the company's total 165 million outstanding shares.The Tevogen.ai

TVGN